60
Participants
Start Date
April 1, 2024
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2027
Acceptance and Commitment Therapy
"Approximately 3 hours of ACT will be administered based on Gregg et al.;s (2007) protocol:~1. What is ACT?~2. Coping and Stress Management~3. Acceptance and Action"
Abbott FreeStyle® Libre® 3
The Abbott FreeStyle® Libre® 3 (FDA approved) consists of a single use disposable electrochemical sensing unit which is placed on the upper arm and an App for smart phones where the participant can view their glucose data, including their current glucose reading, their 'trend arrow' so participants can see how glucose is changing, and their glucose history. The FreeStyle system does not require user calibration. A sensor log will be maintained for accountability of all sensors received as well as used sensors (including the lot/serial number, expiration date, and the date). Sensors will be stored at manufacturers recommendations.
Generic Education
Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
RECRUITING
Sam Houston State University College of Osteopathic Medicine, Conroe
Chelsea Ratcliff, Ph.D.
UNKNOWN
Owen Kelly, Ph.D.,RNutr
UNKNOWN
Oluwaseun Olaiya, DO
UNKNOWN
Michael Griffin, Ph.D.
UNKNOWN
Sam Houston State University
OTHER